DHS Proposal to End 60-Day Grace Period: Implications for Psychedelic Research Talent in the US

Federal Register Proposal: DHS Moves to Eliminate 60-Day Grace Period

The Department of Homeland Security (DHS) has officially proposed eliminating the discretionary 60-day grace period for certain nonimmigrant workers who lose their employment in the United States, as published in the Federal Register on September 11, 2026. This regulatory change would remove 8 CFR 214.1(l)(2), ending a policy that has, since 2017, allowed foreign professionals—including researchers, clinicians, and executives—to remain in the country for up to 60 days after job termination to seek new employment or arrange departure.

The proposal restores the previous standard, tying nonimmigrant status directly to the specific employment or activity that formed the basis of admission. Once employment ceases, so does lawful status, unless another qualifying action is taken immediately. DHS cites the need to reduce administrative burden and reinforce the direct link between visa status and employment.

Mechanism and Context: How the Change Impacts Psychedelic Research Staffing

The 60-day grace period has been a critical buffer for nonimmigrant professionals—such as those on H-1B, O-1, or E-3 visas—working in US-based psychedelic research, clinical trials, and startups. Its removal means that, upon termination or resignation, affected individuals and their dependents would lose lawful status immediately, unless they have already secured new employment or transitioned to another visa category.

Psychedelic research in the US relies heavily on international talent, particularly in specialized scientific and clinical roles. According to National Science Foundation data, over 30% of US postdoctoral researchers in biomedical fields are foreign nationals. The grace period has enabled research institutions and companies to retain top talent during periods of funding uncertainty, grant cycles, or organizational restructuring—common in the fast-evolving psychedelic sector.

A subtle but non-obvious implication is that the loss of the grace period could disproportionately affect smaller startups and academic labs, which often lack dedicated immigration counsel or the resources to expedite hiring and onboarding processes. This could accelerate talent flight to jurisdictions with more flexible immigration policies, such as Canada or the UK, especially in the context of global competition for psychedelic science leadership.

Policy and Research Implications for the Psychedelic Sector

The proposed rule change introduces new legal and operational risks for organizations employing nonimmigrant workers in psychedelic research and clinical development. Institutions will need to reassess hiring timelines, contract structures, and contingency plans to avoid abrupt loss of key personnel. For ongoing clinical trials, sudden staff departures could jeopardize protocol compliance, data continuity, and regulatory submissions, particularly when principal investigators or regulatory affairs experts are affected.

• Compliance Burden: HR and legal teams must now monitor visa-linked employment status in real time, with little margin for error.
• Recruitment Impacts: The US may become less attractive to international researchers, potentially slowing innovation and limiting diversity in psychedelic science.
• Funding and Grant Risks: NIH- or industry-funded projects may face delays or cost overruns if personnel gaps force protocol amendments or re-approvals.

One concrete example: a Phase II clinical trial of psilocybin for major depressive disorder at a US academic center could face a protocol deviation if a foreign-born sub-investigator loses status and must depart mid-study, requiring IRB notification and possible FDA reporting under 21 CFR 312.66.

Risks, Unknowns, and Potential Failure Modes

The most immediate risk is the loss of critical staff with little or no notice, disrupting research continuity and operational planning. For affected individuals, the lack of a grace period increases the likelihood of inadvertent status violations, which can trigger bars on future US entry or eligibility for permanent residency.

Uncertainties remain regarding the final scope of the rule, potential legal challenges, and whether DHS will provide any transition measures for current visa holders. The proposal's rationale—reducing administrative burden—may be tested in court if stakeholders argue that it undermines US competitiveness in science and innovation. Notably, the rule could also create a chilling effect on international recruitment, as prospective hires weigh the risk of abrupt forced departure against opportunities in more accommodating countries.

Forward Look: Preparing for a More Restrictive Immigration Landscape

Organizations in the psychedelic research and clinical sector should immediately review their reliance on nonimmigrant staff and develop risk mitigation strategies. This includes cross-training US-based personnel, expediting green card sponsorship for key talent, and advocating for sector-specific exemptions or legislative relief. Industry groups and academic consortia may wish to submit formal comments during the rulemaking period, highlighting the potential impact on US scientific leadership and public health innovation.

While the regulatory process is ongoing, prudent planning now can reduce the risk of workforce disruptions and ensure compliance if the rule is finalized. The evolving US immigration landscape will remain a critical factor in the global competition for psychedelic research talent.

Authored by Dr. Jamie L. Chen, JD, PhD. Reviewed by Dr. Jamie L. Chen on 2026-09-12. Research based on direct review of the Federal Register proposal and primary agency statements.